xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
